HMI-115 FAQs
← back to HMI-115
6 questions
FAQs
- HMI-115: Frequently Asked Questions About Hair Loss Treatment HMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.
- What is HMI-115 and how is it different from common treatments like minoxidil? HMI-115 (BAY 1158061) is an investigational monoclonal antibody that blocks the prolactin receptor, not a GnRH antagonist. It is given by injection in trials and is not approved anywhere; minoxidil is an approved topical vasodilator with decades of published data, while HMI-115's hair-loss trial results remain unpublished.
- Is HMI-115 taken orally, applied on the scalp, or injected? HMI-115 is administered as an injection.
- Who can benefit the most from HMI-115: men, women, or people in transition? There is no published trial showing that any one group benefits most from HMI-115: the only released human efficacy data is a company press release on a 16-person Phase 1b, and it reported hair-count results for the 12 men only.
- How long does it usually take to see results with HMI-115? Visible results with HMI-115 typically take several months to appear.
- Is HMI-115 considered a safe option, or does it have strong side effects? HMI-115 is an experimental injected antibody, not a hormone blocker: the one published trial (in endometriosis) reported an acceptable 12-week tolerability profile with no treatment-related serious adverse events, and no peer-reviewed safety data exists for its use in hair loss.